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Abstract
Background: Evidence linking breast size to breast cancer risk has been inconsistent, and
its interpretation is often hampered by confounding factors such as body mass index
(BMI). Here, we used linkage disequilibrium score regression and two-sample Mendelian
randomization (MR) to examine the genetic associations between BMI, breast size and
breast cancer risk.
Methods: Summary-level genotype data from 23andMe, Inc (breast size, n¼ 33 790), the
Breast Cancer Association Consortium (breast cancer risk, n¼228 951) and the Genetic
Investigation of ANthropometric Traits (BMI, n¼183 507) were used for our analyses. In
assessing causal relationships, four complementary MR techniques [inverse variance
weighted (IVW), weighted median, weighted mode and MR-Egger regression] were used
to test the robustness of the results.
Results: The genetic correlation (rg) estimated between BMI and breast size was high
(rg¼0.50, P¼3.89x1043). All MR methods provided consistent evidence that higher ge-
netically predicted BMI was associated with larger breast size [odds ratio (ORIVW): 2.06
(1.80–2.35), P¼1.38x1026] and lower overall breast cancer risk [ORIVW: 0.81 (0.74–0.89),
P¼9.44x106]. No evidence of a relationship between genetically predicted breast size
and breast cancer risk was found except when using the weighted median and weighted
mode methods, and only with oestrogen receptor (ER)-negative risk. There was no evi-
dence of reverse causality in any of the analyses conducted (P>0.050).
Conclusion: Our findings indicate a potential positive causal association between BMI
and breast size and a potential negative causal association between BMI and breast can-
cer risk. We found no clear evidence for a direct relationship between breast size and
breast cancer risk.
Key words: Breast size, breast cancer risk, body mass index, Mendelian randomization, LDSC regression, genetic
epidemiology, genetic correlation
Introduction
Observational studies suggest that breast size is related to
breast cancer risk, although the evidence is not consistent
(reviewed in1). Some studies have shown that larger breast
size may be associated with greater breast cancer risk2–4
but others have reported an inverse relationship.5 At the
genetic level, Eriksson et al.6 found that genetic variants as-
sociated with bigger bra cup size were also associated with
increased breast cancer risk. However, the link between
breast size and breast cancer risk becomes less clear when
other factors, such as body mass index (BMI), are consid-
ered at the same time.2,5
On the other hand, BMI has established relationships
with both breast size and breast cancer risk. Generally,
higher BMI is associated with larger breast size.7–9 In a
twin study, the overlap in genetic heritability for BMI and
breast size was estimated to be 33%.10 However, the link
between BMI and breast cancer risk is dependent on
Key Messages
• The relationships between breast size, breast cancer risk and body mass index (BMI) were examined using summary-
level genotype data from three publicly available sources.
• Genetic associations between these three factors were estimated using (i)genetic variants across the entire genome
by linkage disequilibrium score segression, and (ii) only significantly associated variants as instrumental variables in
two-sample Mendelian randomization analysis.
• Women with a genetic predisposition to high BMI are likely to have a larger breast size and a lower risk of breast cancer.
• There is no clear evidence for a direct and unmediated association between breast size and breast cancer risk.
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menopausal status. An inverse relationship is commonly
observed between BMI and premenopausal breast cancer;
a positive relationship is commonly observed between BMI
and postmenopausal breast cancer.11–14 In terms of cancer
subtype, the associations are reported to be stronger for
hormone receptor-positive breast cancer in both pre- and
post-menopausal women.14–16 However, several
Mendelian randomization (MR) analyses showed that BMI
predicted by genome-wide association studies (GWAS)-
identified variants was inversely associated with the risk of
both pre- and post-menopausal breast cancer.17–19
In this study, we examined the genetic interplay between
BMI, breast size and breast cancer risk (Figure 1).
Specifically, we (i) used linkage disequilibrium score regres-
sion (LDSC)20 to estimate genetic correlation by considering
genetic variants across the entire genome, and (ii) assessed
causality using only significantly associated genetic variants
as instruments in two-sample MR analyses.21 Both these
methods have been selected for their respective strengths—
LDSC for the case of complex traits where thousands of var-
iants can have small effects, and MR for its ability to infer
causality given that certain assumptions hold.
Methods
Summary statistics for BMI, breast size and breast
cancer risk
Beta coefficients and standard errors for BMI, breast size
and breast cancer risk for women of European ancestry
were obtained from three publicly available sources:
Genetic Investigation of ANthropometric Traits
(GIANT),22 23andMe (version 4.1)23 and the Breast
Cancer Association Consortium (BCAC).24–26 The genetic
associations with BMI are in standard deviation (SD) units
whereas breast size was coded from 0 to 9, corresponding
to an increase in units of bra cup size: smaller than AAA,
AAA, AA, A, B, C, D, DD, DDD, and larger than DDD.
Breast cancer was coded as a binary phenotype for overall,
oestrogen receptor (ER)-positive and ER-negative breast
cancer. Further details are provided in Supplementary
Table 1, available as Supplementary data at IJE online.
Cross-trait genetic correlation estimated using
LDSC
LDSC, which relies on the adjustment for linkage between
single nucleotide polymorphisms (SNPs), was used to
estimate cross-trait genetic correlations between BMI, breast
size and breast cancer risk (overall, ER-positive, and ER-neg-
ative).20 LDSC estimates genetic correlation by considering
the effects of all SNPs, including those that do not reach
genome-wide significance. SNPs for BMI, breast size and
breast cancer risk, respectively, were merged with HapMap3
SNPs and duplicate reference SNP cluster ids (rsids) were re-
moved using the software provided at https://github.com/
bulik/ldsc (Supplementary Table 1, available as
Supplementary data at IJE online). Linkage disequilibrium
scores provided by the software’s creators, based on the 1000
Genome Project’s European samples, were downloaded from
the same website and cross-trait genetic correlation, rg, was
computed from common SNPs between each pair of traits.
After all preprocessing steps, there were 1 053 312 common
SNPs for BMI and breast size, 992 833 common SNPs for
BMI and all three breast cancer traits, and 1 116 435 com-
mon SNPs for breast size and all three breast cancer traits.
SNP selection
Independent SNPs with genome-wide significant associations
for BMI (n¼77, explaining 2.2% of the variance in BMI)27
and breast size (n¼ 7, explaining 1.2% of the variance in
breast size)6 were used as exposure data for MR analyses. For
outcome, we included 172 breast cancer SNPs.24 After verify-
ing the independence of selected SNPs using the clumping func-
tion in the TwoSampleMR package in R,21 77, 7 and 114
SNPs were retained for further analyses, respectively
(Supplementary Tables 2–4, available as Supplementary data at
IJE online). All 77 BMI SNPs were present in the breast size
and breast cancer risk datasets. All 7 breast size SNPs were pre-
sent in the breast cancer risk dataset, but only 4 were present in
the BMI dataset. A total of 113 breast cancer SNPs were pre-
sent in the breast size dataset and 81 SNPs were present in the
BMI dataset. Before performing MR analyses, the signs of the
beta coefficients for each SNP across all outcome datasets were
aligned to the effective alleles of the exposure datasets.
To assess the MR assumptions, the MR-Egger test was
used to detect directional pleiotropy of the genetic
Figure 1. Relationships between the three traits examined in this study.
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instruments, where a regression intercept that significantly
differs from zero indicates the presence of directional plei-
otropy or the InSIDE assumption (INstrument Strength
Independent of Direct Effect) was violated (i.e. the associa-
tions with other traits that may affect the outcome via
pathways independent of the exposure).28 For the datasets
used in this study, only for the case of BMI (exposure) ver-
sus breast cancer risk (outcome) was the P-value for the
MR-Egger intercept significantly different from zero. The
MR-Pleiotropy RESidual Sum and Outlier (MR-PRESSO)
package in R was used for pleiotropy and outlier SNPs de-
tection for this dataset.29 Six outliers were identified for
BMI (exposure) and overall risk (outcome), four outliers
for BMI (exposure) and ER-positive risk (outcome) and
three outliers for BMI and ER-negative risk (outcome).
After removal of these outliers, the MR-Egger regression
intercept no longer differed significantly from zero. The
MR-PRESSO package was also used to test the other data-
sets, but the MR results did not significantly differ when
outliers identified in these other datasets were removed.
Mendelian randomization
MR was first performed using the inverse-variance weighted
(IVW) method.30 The IVW method assumes that the MR
assumptions are satisfied or that all SNPs are valid instru-
ments. As it is difficult to test the validity of this assumption,
three additional MR methods were also used to assess
the robustness of the result from the primary analysis
under alternative assumptions: weighted median function,31
weighted mode function32 and MR-Egger regression.28
According to Hartwig et al.,32 the weighted median function
provides a valid result under the assumption that >50% of
the weight in the model comes from SNPs that satisfy the
MR assumptions. The weighted mode function is valid if
the majority of SNPs with similar individual causal effect
estimates are valid instruments even if other SNPs in the
model do not meet the requirements for causal inference
using MR. MR-Egger regression allows for horizontal pleio-
tropic effects. As long as this pleiotropy is not correlated
with SNP-exposure associations, the beta-coefficient from
the MR-Egger analysis is valid even if horizontal pleiotropy
exists. Both forward and reverse causality for each pair of
variables were investigated. The above statistical analyses
were performed using TwoSampleMR package in R.21
Results
BMI is genetically correlated with breast size
Genetically predicted BMI and genetically predicted breast
size were correlated [correlation coefficient (rg) ¼ 0.50,
P¼ 3.89x1043] (Figure 2 and Supplementary Table 5,
available as Supplementary data at IJE online) but none of
the other pairs of genetically predicted variables (BMI and
breast cancer risk, breast size and breast cancer risk) was
found by LDSC to be correlated (P> 0.050). As expected,
the genetic correlations between the three types of breast
cancer (overall, ER-positive, ER-negative) were high
(rg>0.60, all P< 10–85) (Figure 2 and Supplementary
Table 5, available as Supplementary data at IJE online).
BMI has a positive effect on breast size but not
vice versa
A 1-SD increase in genetically predicted BMI was strongly as-
sociated with an increase in genetically predicted breast size
{odds ratio (ORIVW) [95% confidence interval (CI)]: 2.06
(1.802.35), P¼ 1.38x1026, Figure 3}. This result was cor-
roborated by other MR methods, namely, weighted median
[ORweighted median: 1.99 (1.64 2.42), P¼ 3.29x1012],
weighted mode [ORweighted mode: 1.94 (1.49–2.51),
P¼ 3.82x106] and MR-Egger [ORMR-Egger: 2.07
(1.532.80), P¼ 1.04x105] (Figures 3 and 4). The MR-
Egger intercept test (P¼0.964) suggested an absence of
strong directional pleiotropy and leave-one-out permutation
analysis (Figure 5) did not detect any single SNP that had a
strong influence on the results. For the reverse direction, re-
gression coefficients close to zero with non-significant P-val-
ues were obtained when breast size was used as exposure
(Supplementary Figures 1 and 2, available as Supplementary
data at IJE online).
Figure 2. Genetic correlations between body mass index (BMI), breast
size and breast cancer risk (overall, ER-positive and ER-negative).
Colour intensity indicates correlation strength, with red indicating posi-
tive correlation (from 0 to þ1) and yellow indicating negative correlation
(from 0 to 1). Significant relationships (P< 0.05) are denoted by
asterisks.
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Figure 3. Odds ratios (ORs) and 95% confidence intervals (CI) for the association between the exposure body mass index (BMI) and two outcomes
(breast size and breast cancer risk) based on the different Mendelian randomization approaches used in this study. *Value based on causal effect esti-
mate from MR-Egger regression; corresponding MR-Egger intercept value testing presence of directional (bias inducing) pleiotropy not shown.
Figure 4. Scatter plot of SNP-breast size associations against SNP-body mass index (BMI) associations with estimates from different Mendelian ran-
domization methods indicated by corresponding coloured lines.
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Figure 5. Leave-one-out permutation analysis plot for breast size obtained by leaving out the SNP indicated and repeating the standard inverse-vari-
ance weighted method with the rest of the 76 SNP instrumental variables.
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BMI has a negative effect on breast cancer risk but
not vice versa
In the IVW analysis, an increase in genetically predicted
BMI was strongly associated with a decrease in overall
[ORIVW: 0.81 (0.74 0.89), P¼ 9.44x106], ER-positive
[ORIVW: 0.79 (0.72–0.88), P¼ 4.84x106] and ER-negative
[ORIVW: 0.78 (0.670.91), P¼1.78x103] breast cancer
risk (Figure 3). Similarly, the estimates derived from other
MR methods did not appreciably differ from the IVW
method (Figures 3 and 6a–c). No evidence for directional
horizontal pleiotropy was observed (P¼ 0.095, 0.219 and
0.108 for BMI-overall, BMI-ER-positive and BMI-ER-
negative breast cancer risk, respectively) and none of the
SNPs had an undue effect on the results (Figure 7a–c). These
results were obtained using 71 SNPs (BMI-overall risk), 73
SNPs (BMI-ER-positive risk) and 74 SNPs (BMI-ER-nega-
tive risk) after removal of outliers as identified by MR-
PRESSO. Before removal of outliers, the MR-Egger inter-
cepts differed significantly from zero (P¼ 0.006, 0.026 and
0.002, respectively). For the reverse direction, regression
coefficients close to zero were obtained when all three risks
were used as exposure, and all P-values were not significant
(all P> 0.070) (Supplementary Figures 3b, 4b, 5b and 6A–
C, available as Supplementary data at IJE online). One of
Figure 6. Scatter plots of SNP-breast cancer risk associations against SNP-body mass index (BMI) associations for (a) overall breast cancer risk, (b)
oestrogen receptor (ER)-positive breast cancer risk, and (c) ER-negative breast cancer risk with estimates from different Mendelian randomization
methods indicated by corresponding coloured lines.
International Journal of Epidemiology, 2019, Vol. 0, No. 0 7
D
ow
nloaded from
 https://academ
ic.oup.com
/ije/advance-article-abstract/doi/10.1093/ije/dyz124/5523691 by Edinburgh U
niversity user on 04 July 2019
the SNPs (rs17817449) appeared to have a stronger effect
compared with the other SNPs from the leave-one-out
analysis (Supplementary Figure 6D–F, available as
Supplementary data at IJE online), and this same outlier
was also detected through MR-PRESSO, but removing it
had a negligible effect on the results.
Unclear relationship between breast size and
breast cancer risk
An increase in genetically predicted breast size was not sig-
nificantly associated with breast cancer risk [ORIVW: 1.23
(0.781.95), P¼ 0.370, 1.19 (0.81–1.74), P¼ 0.373 and
1.32 (0.692.55), P¼ 0.405 for overall, ER-positive and
ER-negative breast cancer risk, respectively] (Figure 8).
The OR estimates obtained from other methods were also
not significant except for those obtained from the weighted
median and weighted mode methods for the breast size-
ER-negative association [ORweighted median: 1.32
(1.071.61), P¼ 0.008 and ORweighted mode: 1.44
(1.191.75), P¼ 0.009] (Figures 8 and 9a–c). No direc-
tional pleiotropic effect was detected as MR-Egger inter-
cept tests did not differ significantly from zero (P¼ 0.991,
0.891 and 0.836 for size-overall, size-ER-positive and size-
ER-negative breast cancer risk, respectively), and no out-
liers were detected by leave-one-out permutation analysis
(Figure 10a–c). For the reverse direction, regression coeffi-
cients close to zero were obtained when all three breast
Figure 7. Leave-one-out permutation analysis plots for (a) overall breast cancer risk, (b) oestrogen receptor (ER)-positive breast cancer risk, and (c)
ER-negative breast cancer risk obtained by leaving out the SNP indicated and repeating the standard inverse-variance weighted method with the rest
of the 70, 72 and 73 SNP instrumental variables used respectively.
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cancer risks were used as exposure and all P-values were
not significant (all P>0.470) (Supplementary Figures 3a,
4a, 5a and 7, available as Supplementary data at IJE
online).
One SNP (rs7816345) was reported to be associated
with both BMI and breast density, which may under-
mine the validity of the instrument for breast size.6,33 In
a sensitivity analysis, removing SNP rs7816345 from the
MR analysis resulted in attenuated results. In other
words, the effect of breast size on ER-negative breast
cancer risk was no longer significant [ORweighted median:
1.16 (0.95–1.43), and ORweighted mode: 0.94 (0.73–
1.23)].
Discussion
In this study, we found potential causal genetic evidence link-
ing BMI to both breast size and breast cancer risk (Figure 11).
Our finding that genetically predicted BMI is positively
correlated with genetically predicted breast size is not sur-
prising given that a number of other epidemiological stud-
ies have reported similar associations. Our analyses extend
the finding of Wade et al.,10 who used data from twin stud-
ies to infer that one third of genes contributing to breast
size were in common with genes influencing BMI. Here,
we used directly all SNPs in common between the two
traits to calculate their genetic correlation after adjusting
for genetic linkage, and found this correlation to be large
and statistically significant. To our knowledge, this is the
first time that empirical genetic data have been used di-
rectly to show a positive association between BMI and
breast size. Additionally, our MR results suggest that a ge-
netic predisposition to higher BMI may be causally linked
to larger breast size, but not the reverse. This direction of
association implies that women with higher BMI have
larger breast size.
We also found through MR analyses a significant rela-
tionship between genetically predicted BMI and breast can-
cer risk. Higher genetically predicted BMI was found to be
inversely associated with the risk of developing both ER-
positive and ER-negative breast cancers. Some studies have
suggested that BMI is more strongly associated with hor-
mone receptor-positive cancers,14,15 but we did not ob-
serve this. Furthermore, although ER-negative breast
cancers are more common in premenopausal women, we
did not find any differences in the (negative) association
between BMI and breast cancer by ER-status. This contra-
dicts the findings from other observational studies that sug-
gest that BMI is positively associated with postmenopausal
breast cancer but negatively associated with premeno-
pausal breast cancer.11–13 It is important to note that the
GWAS summary statistics we used did not directly differ-
entiate between pre- and post-menopausal breast cancer
cases. Nevertheless, our findings are consistent with the
MR analyses of Shu et al.19 Gao et al.18 and Guo et al.17
who, using genetic data, found that BMI was inversely as-
sociated with both pre- and post-menopausal breast cancer
risk. Given that other studies using a similar methodology
have reported this inverse association and that it was inde-
pendent of age, we were not overly surprised by the results.
The protective effect obtained in our study (OR¼ 0.81)
was weaker than that found by Guo et al. (OR¼ 0.65) but
this difference could be due to the different datasets used
as well as Guo et al.’s use of a genetic risk score as an in-
strumental variable instead of the beta-coefficients of each
SNP that we used in our study.
Figure 7. Continued.
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Figure 8. Odds ratios (ORs) and 95% confidence intervals (CI) for the association between breast size and overall breast cancer risk, ER-positive breast can-
cer risk, and ER-negative breast cancer risk based on the different Mendelian randomization approaches used in this study. *Value based on causal effect
estimate from MR-Egger regression; corresponding MR-Egger intercept value testing presence of directional (bias inducing) pleiotropy not shown.
Figure 9. Scatter plots of SNP-breast cancer risk associations against SNP-breast size associations for (a) overall breast cancer risk, (b) oestrogen re-
ceptor (ER)-positive breast cancer risk, and (c) ER-negative breast cancer risk with estimates from different Mendelian randomization methods indi-
cated by corresponding coloured lines.
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The positive association between BMI and breast cancer
risk in postmenopausal women has been speculated to re-
sult from the higher tissue concentrations of oestrogen de-
rived from the larger fat reserves of women with higher
BMI.34 On the other hand, the negative relationship be-
tween BMI and breast cancer risk in premenopausal
women might be explained by lower levels of progesterone
and oestrogen due to the longer anovulatory cycles that
they experience.35,36 In explaining why genetically pre-
dicted BMI was inversely correlated with postmenopausal
risk, Guo et al.17 suggest that the genetic portion of BMI
may reflect an early-life BMI, or that weight gain during
later adulthood and not BMI per se, could be the main fac-
tor leading to increased postmenopausal risk. These
reasons could also explain the results obtained from our
MR analyses. Interestingly, whereas a negative correlation
was estimated between BMI and breast cancer risk using
LDSC, it was not significant (Supplementary Table 5,
available as Supplementary data at IJE online). Also,
MR analysis using breast cancer risk as the exposure
and BMI as the outcome did not produce any significant
associations. Thus, the association between BMI and
breast cancer risk is mediated by only a limited number of
SNPs that are significant for BMI but not for breast cancer
risk.
Breast size is not a commonly considered breast cancer
risk factor.1 Indeed, the relationship between our final pair
of traits, breast size and breast cancer risk, is less clear.
Figure 10. Leave-one-out permutation analysis plots for (a) overall breast cancer risk, (b) oestrogen receptor (ER)-positive breast cancer risk, and (c)
ER-negative breast cancer risk obtained by leaving out the SNP indicated and repeating the standard inverse-variance weighted method with the six
SNP instrumental variables used respectively.
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Eriksson et al.6 reported two SNPs associated with breast
size that were also associated with breast cancer risk, but
when we used all seven SNPs for MR analysis, we were un-
able to detect a significant correlation except when using
the weighted median and weighted mode methods. For
these two methods, there was a positive relationship only
between breast size and ER-negative breast cancer risk.
The weighted median and weighted mode methods
work on the assumption that some of the instrumental var-
iables do not satisfy the requirements for valid MR analy-
sis, but given that only seven SNPs were used for the
analysis, this result has to be interpreted with caution. In
addition, the average pleiotropy was not significantly dif-
ferent from 0, which may imply that there is no directional
pleiotropy and that the estimate from the IVW method is
not biased (i.e. results were consistent with the weighted
median and weighted mode methods). Furthermore,
when we used all SNPs for LDSC regression, no relation-
ship was found as well. Taken together, there is no clear
genetic evidence for a relationship between breast size and
breast cancer risk.
Indeed, the relationship between breast size and breast
cancer risk may be difficult to tease apart without the con-
sideration of mammographic density, which is a strong, in-
dependent risk factor of breast cancer.37 Total breast size
(i.e. area) on a mammogram is a combination of radiologi-
cally dense and non-dense components. Absolute non-dense
area on a mammogram is highly correlated with total breast
area and is inversely associated with breast cancer risk.38
Radiologically dense tissue, on the other hand, contributes
to breast cancer risk.38 It is unclear whether the breast size
instrument currently used is catching size, density or a mix-
ture of both. Future MR analyses examining relationships
between mammographic density measures (i.e. percentage
mammographic density, absolute dense area and absolute
non-dense area) and breast cancer risk will be meaningful.
It is important to note other limitations to our analysis.
Firstly, due to the use of summary statistics, we were not
able to stratify our analyses based on BMI or other breast
cancer risk factors. This could have provided further in-
sight into the nature of the relationship between these two
traits. Secondly, the association between breast size and
breast cancer risk could be driven by environmental factors
that have no genetic component making it undetectable in
this study. Thirdly, the seven SNPs were identified using a
semi-continuous measurement of bra cup size to measure
breast size.6 The lower variability in bra cup size as com-
pared with a continuous variable, such as breast area, may
have resulted in fewer SNPs being identified. However, the
amount of variation in a phenotypic trait that is explained
by genetic variants used in MR analyses is typically small
(<1%, compared with 1.2% for breast size).39
Figure 10. Continued.
Figure 11. Relationships discovered in this study. Significant results
from LDSC regression are denoted by dotted lines and significant
results from MR analysis are denoted by solid arrows.
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Our study is the first to address the potentially causal rela-
tionship between breast size and breast cancer using a MR
approach. In summary, our results suggest that women with
a genetic predisposition to high BMI are likely to have a
larger breast size and a lower risk of breast cancer, but there
is no clear evidence for a direct and unmediated association
between breast size and breast cancer risk. Interestingly, the
reverse causation of breast cancer risk to BMI, breast cancer
risk to breast size and breast size to BMI were all not signifi-
cant, which is in agreement with our intuition. The hypothe-
sis that breast cancer risk is lower in women with both a
larger breast size as well as a genetic predisposition for high
BMI can be tested in future stratified studies.
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